Podcasts
Prevention works, so why don’t we pay for it?
30 June 2026
Grace Hampson is joined by Gundo Weiler, Director of Prevention and Health Promotion at the World Health Organization (WHO) Regional Office for Europe, and Graham Cookson,…
Can HTA keep up with innovation?
23 June 2026
But the pace of innovation often outruns policy – new developments in innovative therapies, digital health technologies, and a shifting geopolitical landscape are pushing HTA systems…
Cost-effectiveness thresholds: theory, pragmatism, and NICE’s new number
16 June 2026
Grace Hampson is joined by Adrian Towse, who ran OHE as its Director for many years, and Chris Sampson, Senior Principal Economist at OHE, to dig into one…
What is your health worth? PROMs, EQ-5D & economic evaluation
9 June 2026
Grace Hampson is joined by David Mott, Associate Director at OHE, as well as Hannah Hussain, an Economist at OHE, both part of OHE’s Measuring and Valuing Outcomes…
AI and the future of health economics
2 June 2026
Grace Hampson is joined by Tim Reason, co-founder and managing director of Estima Scientific, and Dalia Dawoud, Research Principal in HTA Policy and Strategy at Cytel to dive into AI’s incredible potential –…
Should HTA look beyond the healthcare system?
26 May 2026
Grace Hampson is joined by Chris Skedgel, a Director at OHE, to dig into one of health economics’ most contested methodological debates: what are health systems trying to achieve through…
Can joint clinical assessment speed up access to medicines?
19 May 2026
Grace Hampson is joined by Patrick Hopkinson, founder of PHTA Consulting and global market access expert, and Matthias Hofer, Senior Principal Economist at OHE, to take…
When antibiotics stop working: the hidden crisis in plain sight
12 May 2026
Grace Hampson is joined by Lotte Steuten, Deputy CEO of the Office of Health Economics and David McKinney, Co-founder of ARMoR, to dig into the market failures surrounding the AMR crisis and…
Most Favored Nation pricing: what it means for policy, patients and pharma
5 May 2026
US pharmaceutical prices are the highest in the world – President Trump’s Most Favoured Nation (MFN) policy is trying to change that. But what does MFN pricing mean in practice?